



Innovative technologies, products and services to improve human life.

FibroScan[®] Expert 630

The complete non-invasive solution for advanced liver disease management

Powered by unique, patented and validated parameters: LSM by VCTE[™], CAP[™] and SSM by VCTE[™] as part of an overall assessment of the liver.

Ideal solution for high-volume hospital-based settings.



NEW Guided VCTE[™]

The next generation VCTE[™] technology

Intuitive features for faster examinations and simplified scanning¹

- Two new indicators that allow for quick identification of the optimal measurement location
- AutoScan feature which triggers 10 valid measurements through a single click
- SmartExam features fully included: SmartDepth and Continuous CAP[™]



Stiffness indicator



CAP[™] indicator

Enhance exam efficiency

- High-speed processing
- 19 inch touchscreen & washable touch keyboard
- Two probe connectors to easily switch between probes during exam
- For spleen examination: the M+ probe automatically adjusts to 100 Hz, adapts measurement depth, and adjusts the stiffness range

Ultrasound localization probe:

Time-saving technology for easily locating the spleen and liver in complex patients and patients with obesity.

Adapted to all patient morphologies

Probes S+, M+ and XL+



Unique capabilities of SSM by VCTE[™]

Management and risk stratification of patients with advanced chronic liver disease^{2,3,4}

- **Assess and Monitor Portal Hypertension***
SSM by VCTE[™] helps to assess and monitor portal hypertension, the main driver of cirrhosis, in a quick and non-invasive way.
- **Helps to Assess the Presence of Esophageal Varices***
SSM by VCTE[™] can provide added value to help identify high-risk varices and prioritize endoscopies.
- **Determine Surgery***
SSM by VCTE[™] has the potential to triage patients in the general surgical population by assessing portal hypertension, a known risk factor, prior to surgery.

* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.



Enhance your FibroScan[®] experience with the **Liver Health Management platform**

What makes FibroScan® unique?

- A painless exam that can be performed in **less than 4 minutes** with immediate results at the point-of-care.¹
- Can be performed by **any trained operator** (physician, nurse, or medical assistant).
- Standardized examination with exceptional precision and reproducibility that can be utilized in **99% of patients**.⁵
- An **ecosystem of solutions** developed by Echosens to support clinical decisions for physicians: Liver Health Management platform, Scores by Echosens^{6,7}, Interpretation Guide, myFibroScan, FibroScan® Gateway and educational support.



Renowned Publication Presence & Endorsement in Clinical Practice Guidelines

4,200+ peer-reviewed publications

180+ international guidelines

More than 4,200 peer-reviewed publications and 180 international guidelines advocate the use of FibroScan® as the reference non-invasive solution for liver fibrosis, cirrhosis, and steatosis assessment across all etiologies of chronic liver disease (viral hepatitis, MASLD/MASH, alcoholic liver disease).^{4,8,9}

AASLD

ADA

AHA

APASL

EASL

AACE


AGA

AISF

Baveno VII

NICE Guidance

Examinations with FibroScan® can inform treatment decisions across the spectrum of disease



Interested in FibroScan® Expert 630 for your practice?
Contact us on info@sanaremedical.com

LSM: Liver Stiffness Measurement / VCTE™: Vibration Controlled Transient Elastography / CAP™: Controlled Attenuation Parameter / SSM: Spleen Stiffness Measurement / MASLD: Metabolic dysfunction-associated steatotic liver disease (formerly known as NAFLD) / MASH: Metabolic dysfunction-associated steatohepatitis (formerly known as NASH) / LHM: Liver Health Management

References

1. Based on internal data. E431R020.1. 2. Stefanescu H, et al. A novel spleen-dedicated stiffness measurement by FibroScanR improves the screening of high-risk oesophageal varices. *Liver Int.* 2020;40(1):175-185. doi:10.1111/ liv.14228. 3. Dajti, Elton et al. "A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease." *The American journal of gastroenterology* vol. 117,11 (2022): 1825-1833. doi:10.14309/ajg.0000000000001887. 4. Baveno VII - R. de Franchis et al. Renewing consensus in portal hypertension. *Journal of hepatology* vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022. 5. Myers, Robert P et al. "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients." *Hepatology (Baltimore, Md.)* vol. 55,1 (2012): 199-208. doi:10.1002/hep.24624. 6. Newsome, Philip N et al. "FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study." *The Lancet. Gastroenterology & hepatology* vol. 5,4 (2020): 362-373. doi:10.1016/S2468-1253(19)30383. 7. Sanyal, Arun J et al. "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores." *Journal of hepatology* vol. 78,2 (2023): 247-259. doi:10.1016/j.jhep.2022.10.034. 8. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu et al. "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update." *Journal of hepatology* vol. 75,3 (2021): 659-689. 9. Kanwal, Fasiha et al. "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease." *Gastroenterology* vol. 161,5 (2021): 1657-1669.

The FibroScan® 630 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™) at 50 Hz shear wave frequency and liver ultrasound attenuation coefficient (CAP™) at 3.5 MHz. FibroScan® 630 Expert is also intended to measure spleen stiffness using VCTE™ at 100 Hz shear wave frequency. FibroScan liver stiffness measurements (LSM) by VCTE™ may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided. * CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available with SmartExam capability. FibroScan® Gateway is a Non-Device Medical Device Data Systems (MDDS) and Interpretation Guide (included within myFibroScan application) are Non-Device Clinical Decision Support (CDS) that meet the criteria outlined in section 520(o)(1)(E) of the FD&C Act. ©2024 Echosens. All rights reserved. Echosens™, FibroScan®, among others, are trademarks and/or service mark of Echosens Group and are registered in the U.S. and/or other countries. One-pager FibroScan® Expert 630 - v1 USA - 12/2023.





**SANARE
MEDICAL**

SANARE MEDICAL PVT LTD

Website : www.sanaremedical.com

Email : info@sanaremedical.com

Tel : +91 9810275300 , +91 98101 37486

Corp. Office: E-354 Greater kailash Part 1
New Delhi 110048

Regd. Office : DP 61 Phase 1 Udyog Vihar
Gurugram Haryana 122001